Tenofovir Alafenamide;
$300.00
CAS No.: 379270-37-8
Catalog No.: TQP0858
Purity: 95%
MF: C21H29N6O5P
MW: 476.474
Storage: 2-8 degree Celsius
SMILES: NC1=C2N=CN(C2=NC=N1)C[C@@H](C)OCP(=O)(OC1=CC=CC=C1)N[C@H](C(=O)OC(C)C)C
Catalog No.: TQP0858
Purity: 95%
MF: C21H29N6O5P
MW: 476.474
Storage: 2-8 degree Celsius
SMILES: NC1=C2N=CN(C2=NC=N1)C[C@@H](C)OCP(=O)(OC1=CC=CC=C1)N[C@H](C(=O)OC(C)C)C
CAS No.: 379270-37-8; Tenofovir Alafenamide. PROPERTIES: Tenofovir Alafenamide is a white crystalline powder with a molecular formula of C21H23FN6O5P and a molecular weight of 534.41 g/mol. It has a melting point between 142-146 C and limited water solubility (approximately 0.4 mg/mL). The compound is sensitive to acidic conditions and requires storage at 2-8 C in airtight containers protected from light. Safety precautions include using respiratory protection during handling to prevent inhalation, as the compound is classified as a Category 4 acute toxicity (inhalation) hazard. APPLICATIONS: Tenofovir Alafenamide is primarily used as an antiviral prodrug in the treatment of HIV-1 infection. Its mechanism involves intracellular conversion to the active tenofovir diphosphate, which inhibits viral reverse transcriptase, as detailed in Antimicrobial Agents and Chemotherapy. Clinical guidelines from the International Antiviral Society recommend its use as part of combination antiretroviral therapy due to its favorable resistance profile and safety. Research in the Journal of Infectious Diseases has also explored its potential in treating chronic hepatitis B, demonstrating viral load reduction with improved renal and bone safety compared to earlier tenofovir formulations. Additionally, Tenofovir Alafenamide has been investigated for its potential in preventing mother-to-child transmission of HIV, with studies in the Journal of Acquired Immune Deficiency Syndromes showing promising efficacy in resource-limited settings.
Reviews
Write Your Own Review